Barton K., Winckelmann A., Palmer S. HIV-1 Reservoirs During Suppressive Therapy // Trends Microbiol. 2016. Vol. 24. No. 5. Р. 345–355.

Doyle, T. Geretti, A. M. Low-level viraemia on HAART: significance and management // Curr. Opin. Infect. Dis. 2012. Vol. 25. No. 1. Р. 17–25.

Sarmati L., D’Ettorre G., Parisi S.G. et al. HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective // Curr. HIV Res. 2015. Vol. 13. No. 3. Р. 250–257.

Spivak A.M., Planelles V. HIV-1 Eradication: Early Trials (and Tribulations) // Trends Mol. Med. 2016. Vol. 22. No. 1. Р. 10–27.

Trono D., Van Lint C., Rouzioux C. et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals //Science. 2010. Vol. 329. No. 5988. Р. 174–180.

Sahu G.K. Potential implication of residual viremia in patients on effective antiretroviral therapy // AIDS Res Hum Retroviruses. 2015. Vol. 31. No. 1. Р. 25–35.

Pham H.T., Mesplede T. The latest evidence for possible HIV-1 curative strategies // Drugs Context. 2018. Vol. 7. Р. 212522.

Costiniuk C.T., Jenabian M.A. HIV reservoir dynamics in the face of highly active antiretroviral therapy // AIDS Patient Care STDS. 2015. Vol. 29, Nо. 2. Р. 55–68.

Rose R., Nolan D.J., Maidji E. et al. Eradication of HIV from Tissue Reservoirs: Challenges for the Cure // AIDS Res Hum Retroviruses. 2018. Vol. 34, Nо. 1. Р. 3–8.

Castro-Gonzalez S., Colomer-Lluch M., Serra-Moreno R. Barriers for HIV Cure: The Latent Reservoir // AIDS Res Hum Retroviruses. 2018. Vol. 34. No. 9. Р. 739–759.

Romani B., Allahbakhshi E. Underlying mechanisms of HIV-1 latency // Virus Genes. 2017. Vol. 53. No. 3. Р. 329–339.

Van Marle G., Church D. L., van der Meer F. et al. Combating the HIV reservoirs // Biotechnol Genet Eng. Rev. 2018. Vol. 34. No. 1. Р. 76–89.

Deeks S.G., Lewin S.R., Ross A.L. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016 // Nat. Med. 2016. Vol. 22. No. 8. Р. 839–850.

Kimata J.T., Rice A.P., Wang J. Challenges and strategies for the eradication of the HIV reservoir // Curr. Opin. Immunol. 2016. Vol. 42. Р. 65–70.

Allers K., Hutter G., Hofmann J. et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation // Blood. 2011. Vol. 117. Nо. 10. Р. 2791–2799.

Yukl S.A., Boritz E., Busch M. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient // PLoS Pathog. 2013. Vol. 9. Nо. 5. pp. e1003347.

Gupta R.K., Abdul-Jawad S., McCoy L.E. et al. HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation // Nature. 2019. Vol. 568. Nо. 7751. Р. 244–248.

Wang H., Yang H. Gene-edited babies: What went wrong and what could go wrong // PLoS Biol. 2019. Vol. 17. Nо. 4. Р. e3000224.

Li J.R., Walker S., Nie J.B. et al. Experiments that led to the first gene-edited babies: the ethical failings and the urgent need for better governance // J. Zhejiang Univ Sci. B. 2019. Vol. 20. Nо. 1. Р. 32–38.

Jean M.J., Fiches G., Hayashi T. et al. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors // AIDS Res Hum Retroviruses. 2019. Vol. 35. Nо. 1. Р. 1–24.

Saez-Cirion A., Bacchus C., Hocqueloux L. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study // PLoS Pathog. 2013. Vol. 9. Nо. 3. Р. e1003211.

Darcis G., Van Driessche B., Van Lint C. HIV Latency: Should We Shock or Lock? // Trends Immunol. 2017. Vol.38. Nо. 3. Р. 217–228.

Perreau M., Banga R., Pantaleo G. Targeted Immune Interventions for an HIV-1 Cure // Trends Mol. Med. 2017. Vol. 23. Nо. 10. Р. 945–961.

Delagreverie H.M., Delaugerre C., Lewin S.R. et al. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents // Open Forum Infect. Dis. 2016. Vol. 3. Nо. 4. Р. ofw189.

Margolis D.M., Garcia J.V., Hazuda D.J. et al. Latency reversal and viral clearance to cure HIV-1 // Science. 2016. Vol. 353. Nо. 6297. Р. aaf6517.

Barton K.M., Palmer S.E. How to Define the Latent Reservoir: Tools of the Trade // Curr. HIV/AIDS Rep. 2016. Vol. 13. Nо. 2. Р. 77–84.

Siliciano J.D., Siliciano R.F. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication- competent virus in HIV-1-infected individuals // Methods Mol. Biol. 2005. Vol. 304. Р. 3–15.

Kiselinova M., Pasternak A.O., De Spiegelaere W. et al. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA // PLoS One. 2014. Vol. 9. Nо. 1. Р. e85999.

Rouzioux C., Avettand-Fenoel V. Total HIV DNA: a global marker of HIV persistence // Retrovirology. 2018. Vol. 15. Nо. 1. Р. 30.

Sharaf R.R., Li J.Z. The Alphabet Soup of HIV Reservoir Markers // Curr. HIV/AIDS Rep. 2017. Vol. 14. Nо. 2. Р. 72–81.

Hodel F., Patxot M., Snaka T. et al. HIV-1 latent reservoir: size matters // Future Virol. 2016. Vol. 11. Nо. 12. Р. 785–794.

Cromer D., Pinkevych M., Rasmussen T.A. et al. Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission? // J. Virol. 2017. Vol. 91. No. 24.

Li J.Z., Etemad B., Ahmed H. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption // AIDS. 2016. Vol. 30. No. 3. Р. 343–353.

Salantes D.B., Zheng Y., Mampe F. et al. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption // J. Clin. Invest. 2018. Vol. 128. Nо 7. Р. 3102–3115.